The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index; 13 of the 27 sources its claims cite were checked for support.
NRK1 controls nicotinamide mononucleotide and nicotinamide riboside metabolism in mammalian cells
Open accessAbstract
Here we show that nicotinamide riboside kinase 1 (NRK1) is necessary and rate-limiting for the use of exogenous NR and NMN for NAD+ synthesis. Using stable isotope-labelled compounds, we confirm NMN is metabolized extracellularly to NR that is then taken up by the cell and converted into NAD+.
Overview
CoChat Summary
## TL;DR
NRK1 is the key rate-limiting enzyme that mammalian cells and liver require to convert exogenous nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) into NAD+. The paper shows that NMN is first dephosphorylated extracellularly to NR, which is then taken up and used for NAD+ synthesis.
## Key findings
- In NIH/3T3 cells, overexpression of active NRK1 or NRK2 converted NR-nonresponsive cells into NR-responsive cells, producing about a 4-fold increase in NAD+; catalytically inactive NRK1-D36A and NRK2-D35A did not.
- In F3T3-NRK1 cells, NR increased NAD+ at concentrations as low as 100 μM, with maximal effects at about 1 mM; NMN increased NAD+ only in NRK1-overexpressing cells and less potently than NR, while NAM worked regardless of NRK1.
- In primary hepatocytes from NRK1KO mice, NR and NMN failed to increase NAD+, whereas NA and NAM still increased NAD+ normally.
- In vivo, 500 mg kg−1 intraperitoneal NR raised liver NAD+ by about 220% in wild-type mice; NMN and NAM raised it by about 170%, and NR/NMN responses were significantly blunted in NRK1KO mice, though about 60% of the NR and NMN effect remained.
## Methods
- The study used gain- and loss-of-function models: transient and stable NRK1/NRK2 overexpression in cell lines, siRNA knockdown of Nmrk1 in AML12 hepatocytes, and a constitutive Nmrk1 knockout mouse.
- NAD+ precursor metabolism was tested in cultured cells, primary hepatocytes, primary brown adipocytes, and mice using NR, NMN, NAM, and NA treatments, plus isotope-labeled compounds for flux analysis.
- Main analyses included NAD+ quantification by assay, targeted LC-MS/LC-QqQ MS metabolomics, western blotting, and qPCR; statistical testing used t-tests or one-way ANOVA with Bonferroni post-test.
## Limitations
- The paper states that data are available only upon request, which limits immediate reproducibility access.
- The text makes evident that several mechanistic claims rely on high-dose precursor injections in mice (e.g., 500 mg kg−1 and 50 mg kg−1), so some in vivo effects may not reflect physiological exposure; this is evident from the text.
- The paper itself notes that future work is needed to better characterize circulating NAD+, NMN, and NR and to optimize organ-targeted formulations.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



![Figure 4 Extracellular NMN dephosphorylates to NR. HepG2 cells were treated with [18O]-labelled NR (a,b) or NMN (c,d). Intracellular enrichment of labelled compounds (a,c) and presence of labelled compounds in the media of treated cells (b,d). Results shown are mean±s.e.m. (n=3).](https://figures.cochat.ai/paper-figures/57e8a39cf3da45969cbff31a92059db8/nrk1-controls-nicotinamide-mononucleotide-and-nicotinamide-riboside-metabolism-figure-4.jpg)

![Figure 6 Extracellular conversion of NMN to NR by hepatocytes. (a) Primary hepatocytes were isolated from 10 to 15 weeks old WT mice. Cells were treated with 2 μM FK866 and ±2 mM CMP for 1 h. Then, 0.5 mM NR or NMN was added and NAD+ was measured after 2 h. (b,c) WT (b) and NRK1KO (c) hepatocytes were treated with [2H]-[13C]-double labelled NR or NMN. Intracellular enrichment of labelled compounds. Results shown are mean±s.e.m., **P<0.01 versus ctrl by two-sided unpaired T-test (n=3).](https://figures.cochat.ai/paper-figures/d72a2197ccbc48f5bcf199a67d302e52/nrk1-controls-nicotinamide-mononucleotide-and-nicotinamide-riboside-metabolism-figure-6.jpg)


Verification
Claims the paper makes
12 Valid · 1 Not valid · 12 Not checked · 97 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Whereas NMN concentration has been reported to reach around 50 μM in plasma14, our study and others13 have failed to detect comparable levels of circulating NMN.”
§ NRK1 controls nicotinamide mononucleotide and nicotinamide riboside metabolism in mammalian cells > Discussion
What the sources say
- Not checked — no full text of the sourcecites [14] Revollo, J. R. et al. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab. 6, 363–375 (2007). source
- Supportedcites [13] Hara, N., Yamada, K., Shibata, T., Osago, H. & Tsuchiya, M. Nicotinamide phosphoribosyltransferase/visfatin does not catalyze nicotinamide mononucleotide formation in blood plasma. PLoS ONE 6, e22781 (2011). source
The Results section reports that NMN was not detected in freshly prepared mouse plasma by LC/MS/MS, with a detection limit of 50 nM—far below the approximately 50 µM level mentioned in the citing sentence. The Discussion likewise contrasts this nondetection with earlier reports of high plasma NMN concentrations. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In line with this, CD73 silencing blocks the use of NMN as an extracellular NAD+ precursor17.”
§ NRK1 controls nicotinamide mononucleotide and nicotinamide riboside metabolism in mammalian cells > Discussion
What the sources say
- Partly supportedcites [17] Sociali, G. et al. Antitumor effect of combined NAMPT and CD73 inhibition in an ovarian cancer model. Oncotarget 7, 2968–2984 (2015). sourceExperimental — accuracy not yet measured
The Results section (Figure 2D) reports that CD73 silencing reduced by 70% the ability of FK866-treated OVCAR-3 cells to generate intracellular NAD+ from extracellular NMN. This supports impaired use of NMN, but not the claim that silencing completely blocks it. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the induction of NRK2 in response to cellular damage or stress32 suggests the existence of a demand for circulating NR.”
§ NRK1 controls nicotinamide mononucleotide and nicotinamide riboside metabolism in mammalian cells > Discussion
What the sources say
- Supportedcites [32] Sasaki, Y., Araki, T. & Milbrandt, J. Stimulation of nicotinamide adenine dinucleotide biosynthetic pathways delays axonal degeneration after axotomy. J. Neurosci. 26, 8484–8491 (2006). source
The Results section, “Expression of enzymes involved in NAD biosynthesis is induced in response to neuronal injury” (page not provided), reports that Nrk2 expression rose more than 20-fold after axotomy. The Discussion interprets this as part of the neuronal response to stress. The sentence’s suggestion of demand for circulating NR is the citing authors’ inference, not a finding it attributes to this source. (LLM, conf=0.93)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“This experiment, conducted in parallel with a human clinical trial at the same effective dose of NR, showed that NR produces the greatest rise in liver NAD+ synthesis, followed by NAM and NA24.”
§ NRK1 controls nicotinamide mononucleotide and nicotinamide riboside metabolism in mammalian cells > Discussion
What the sources say
- Supportedcites [24] Trammell, S. A. et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat. Commun. 7, 12948 (2016). source
The Results section ('NR is the superior hepatic NAD+ precursor vitamin'; page not supplied) says the mouse dose was chosen to be comparable, after body-size adjustment, to an effective human NR dose, and that mice received NR or equimolar NAM and NA. The Discussion (page not supplied) ranks their effects on mouse liver NAD+ as NR, then NAM, then NA. The paper also reports a human clinical trial; it does not establish that the mouse experiment and trial ran at the same time. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, WT mice and NRK1/NRK2DKO displayed comparable increases in NAD+ levels in skeletal muscle after intraperitoneal NR and NMN administration (Supplementary Fig. 3d).”
§ NRK1 controls nicotinamide mononucleotide and nicotinamide riboside metabolism in mammalian cells > Results > NRK1KO mice are deficient in NR and NMN utilization in vivo
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
50 more claims
Create a free account to see all 122 claims and every source verdict.
- Probably not a substantial claim. 25
- It may state two separate claims as one. 49
- Borderline: one of the tests for a substantial claim is unclear. 1
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Experimental evidence suggests that blood NA and NAM are able to cross the plasma membrane, while blood NAD+ cannot be taken up by cells directly but needs to be converted to smaller uncharged molecules to enter the cells (Hara et al., 2007; Ratajczak et al., 2016).”
From NAD+ in Brain Aging and Neurodegenerative Disorders (2019) · cites this paper as Ratajczak et al., 2016
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a previous study, the deficiency of NRK1, which phosphorylates NR to NMN, diminished the increase of NAD+ levels in the liver after oral NMN administration, suggesting that NMN was converted to NR before absorption (11).”
From Nicotinamide riboside and nicotinamide mononucleotide facilitate NAD + synthesis via enterohepatic circulation (2025) · cites this paper as [11]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Meanwhile, NR is converted to NMN by NR kinase (NRK), thereby bypassing the NAMPT-mediated step (11, 12).”
From Nicotinamide riboside and nicotinamide mononucleotide facilitate NAD + synthesis via enterohepatic circulation (2025) · cites this paper as [11]
In the citing paper
“Additionally, nicotinamide riboside (NR) integrates in this pathway via the conversion of NR into NMN by nicotinamide riboside kinase 1 (NRK1) or NRK2 (Bieganowski and Brenner, 2004; Ratajczak et al., 2016).”
From NAD+ in Brain Aging and Neurodegenerative Disorders (2019) · cites this paper as Ratajczak et al., 2016
Citations
Cites
HIGH-YIELD PREPARATION OF ISOLATED RAT LIVER PARENCHYMAL CELLS
Berry, M. N., & Friend, D. S. (1969) · The Journal of Cell Biology · doi:10.1083/jcb.43.3.506 · Cited by 4,424
Mammalian Sirtuins: Biological Insights and Disease Relevance
Haigis, M. C., & Sinclair, D. A. (2010) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092250 · Cited by 2,085 · cited 1×
“Importantly, sirtuin activation has been associated with an improvement in metabolic efficiency and healthspan in mammals 4,5 .”
Sirtuins as regulators of metabolism and healthspan
Houtkooper, R. H., Pirinen, E., & Auwerx, J. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3293 · Cited by 2,008
Self-citationCantó, C., Menzies, K. J., & Auwerx, J. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.05.023 · Cited by 1,648
Self-citationGomes, A. P., Price, N. L., Ling, A. J. Y., Moslehi, J. J., Montgomery, M. K., Rajman, L., White, J. P., Teodoro, J. S., Wrann, C. D., Hubbard, B. P., et al. (2013) · Cell · doi:10.1016/j.cell.2013.11.037 · Cited by 1,482
NAD+ and sirtuins in aging and disease
Imai, S.-I., & Guarente, L. (2014) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.04.002 · Cited by 1,481
Yoshino, J., Mills, K. F., Yoon, M. J., & Imai, S.-I. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.08.014 · Cited by 1,340
NAD + repletion improves mitochondrial and stem cell function and enhances life span in mice
Zhang, H., Ryu, D., Wu, Y., Gariani, K., Wang, X., Luan, P., D’Amico, D., Ropelle, E. R., Lutolf, M. P., Aebersold, R., et al. (2016) · Science · doi:10.1126/science.aaf2693 · Cited by 1,255
Self-citationCantó, C., Houtkooper, R. H., Pirinen, E., Youn, D. Y., Oosterveer, M. H., Cen, Y., Fernandez-Marcos, P. J., Yamamoto, H., Andreux, P. A., Cettour-Rose, P., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.04.022 · Cited by 1,238
Self-citationMouchiroud, L., Houtkooper, R. H., Moullan, N., Katsyuba, E., Ryu, D., Cantó, C., Mottis, A., Jo, Y.-S., Viswanathan, M., Schoonjans, K., et al. (2013) · Cell · doi:10.1016/j.cell.2013.06.016 · Cited by 1,210
Self-citation
Cited by
NAD+ metabolism and its roles in cellular processes during ageing
Covarrubias, A. J., Perrone, R., Grozio, A., & Verdin, E. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-00313-x · Cited by 1,617
NAD(H) and NADP(H) Redox Couples and Cellular Energy Metabolism
Xiao, W., Wang, R.-S., Handy, D. E., & Loscalzo, J. (2018) · Antioxidants & Redox Signaling · doi:10.1089/ars.2017.7216 · Cited by 1,061
“In mice, injection of NR augmented NAD levels in the muscle, liver, brain, and brown adipose tissue, an effect that was abrogated in NRK1 knockout mice (108).”
BackgroundNAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR
Yoshino, J., Baur, J. A., & Imai, S.-I. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.11.002 · Cited by 1,061
“…2016 C57BL/6NTac wild-type and Nrk1 KO, or Nrk1/2 double KO mice male 500 mg/kg, 50 mg/kg (IP) 1 hr some degradation of NR to NAM detectable in plasma Ratajczak et al., 2016 C57BL/6JRcc mice fed a medium-/highfat diet male 5–900 ppm (diet) 30 ppm for 4 weeks, then stratified to test groups for…”
InfluentialNAD+ metabolism: pathophysiologic mechanisms and therapeutic potential
Xie, N., Zhang, L., Gao, W., Huang, C., Huber, P. E., Zhou, X., Li, C., Shen, G., & Zou, B. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00311-7 · Cited by 1,052
“NR, which can cross the cell membrane through a dypiridamole-inhibitable nucleoside transporter, is preferentially used by muscle to synthesize NAD.(98) Accordingly, the NR-using enzyme, NRK2, is usually specifically expressed in the skeletal muscle.”
BackgroundTherapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence
Rajman, L., Chwalek, K., & Sinclair, D. A. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.02.011 · Cited by 865
“In rodents, NR is more efficient in boosting NAD+ than NA and NAM (Trammell et al., 2016a), possibly due to increased uptake (Imai, 2009; Imai and Guarente, 2014; Ratajczak et al., 2016; Revollo et al., 2007a).”
InfluentialNAD+ in Brain Aging and Neurodegenerative Disorders
Lautrup, S., Sinclair, D. A., Mattson, M. P., & Fang, E. F. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.09.001 · Cited by 790
Nicotinamide riboside is uniquely and orally bioavailable in mice and humans
Trammell, S. A. J., Schmidt, M. S., Weidemann, B. J., Redpath, P., Jaksch, F., Dellinger, R. W., Li, Z., Abel, E. D., Migaud, M. E., & Brenner, C. (2016) · Nature Communications · doi:10.1038/ncomms12948 · Cited by 697
Self-citationNAD+ homeostasis in health and disease
Katsyuba, E., Romani, M., Hofer, D., & Auwerx, J. (2020) · Nature Metabolism · doi:10.1038/s42255-019-0161-5 · Cited by 627
Self-citationQuantitative Analysis of NAD Synthesis-Breakdown Fluxes
Liu, L., Su, X., Quinn, W. J., Hui, S., Krukenberg, K., Frederick, D. W., Redpath, P., Zhan, L., Chellappa, K., White, E., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.018 · Cited by 564
Self-citationMartens, C. R., Denman, B. A., Mazzo, M. R., Armstrong, M. L., Reisdorph, N., McQueen, M. B., Chonchol, M., & Seals, D. R. (2018) · Nature Communications · doi:10.1038/s41467-018-03421-7 · Cited by 588
Elhassan, Y. S., Kluckova, K., Fletcher, R. S., Schmidt, M. S., Garten, A., Doig, C. L., Cartwright, D. M., Oakey, L., Burley, C. V., Jenkinson, N., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.043 · Cited by 448
“Although it is clear in rodent models that NR requires NR kinase activity in muscle (Ratajczak et al., 2016; Fletcher et al., 2017), further studies are required to understand NR dynamics in human muscle cells and tissues.”
BackgroundSelf-citationSenescent cells promote tissue NAD+ decline during ageing via the activation of CD38+ macrophages
Covarrubias, A. J., Kale, A., Perrone, R., Lopez-Dominguez, J. A., Pisco, A. O., Kasler, H. G., Schmidt, M. S., Heckenbach, I., Kwok, R., Wiley, C. D., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-00305-3 · Cited by 420
Self-citationNicotinamide Riboside Preserves Cardiac Function in a Mouse Model of Dilated Cardiomyopathy
Diguet, N., Trammell, S. A. J., Tannous, C., Deloux, R., Piquereau, J., Mougenot, N., Gouge, A., Gressette, M., Manoury, B., Blanc, J., et al. (2018) · Circulation · doi:10.1161/circulationaha.116.026099 · Cited by 358
Self-citationNicotinamide Improves Aspects of Healthspan, but Not Lifespan, in Mice
Mitchell, S. J., Bernier, M., Aon, M. A., Cortassa, S., Kim, E. Y., Fang, E. F., Palacios, H. H., Ali, A., Navas-Enamorado, I., Di Francesco, A., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.02.001 · Cited by 338
“Quantitative metabolomic analysis has made it clear that oral NR boosts hepatic NAD metabolism and sirtuin activity independently of NAMPT (Ratajczak et al., 2016; Fletcher et al., 2017), thereby leading to a wave of hepatic NAM production (Trammell et al.”
BackgroundSelf-citationEvolving concepts in NAD+ metabolism
Chini, C. C. S., Zeidler, J. D., Kashyap, S., Warner, G., & Chini, E. N. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.04.003 · Cited by 288
Slc12a8 is a nicotinamide mononucleotide transporter
Grozio, A., Mills, K. F., Yoshino, J., Bruzzone, S., Sociali, G., Tokizane, K., Lei, H. C., Cunningham, R., Sasaki, Y., Migaud, M. E., et al. (2019) · Nature Metabolism · doi:10.1038/s42255-018-0009-4 · Cited by 287
Self-citationNAD+ augmentation restores mitophagy and limits accelerated aging in Werner syndrome
Fang, E. F., Hou, Y., Lautrup, S., Jensen, M. B., Yang, B., SenGupta, T., Caponio, D., Khezri, R., Demarest, T. G., Aman, Y., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13172-8 · Cited by 275
Braidy, N., Berg, J., Clement, J., Khorshidi, F., Poljak, A., Jayasena, T., Grant, R., & Sachdev, P. (2019) · Antioxidants & Redox Signaling · doi:10.1089/ars.2017.7269 · Cited by 275
“Another study showed that NMN is metabolized extracellularly to yield NR, which is then converted to NAD intracellularly (272).”
BackgroundMethodInfluentialNAD metabolism: Implications in aging and longevity
Yaku, K., Okabe, K., & Nakagawa, T. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.05.006 · Cited by 269
Airhart, S. E., Shireman, L. M., Risler, L. J., Anderson, G. D., Nagana Gowda, G. A., Raftery, D., Tian, R., Shen, D. D., & O’Brien, K. D. (2017) · PLOS ONE · doi:10.1371/journal.pone.0186459 · Cited by 259
NAD + Metabolism in Cardiac Health, Aging, and Disease
Abdellatif, M., Sedej, S., & Kroemer, G. (2021) · Circulation · doi:10.1161/circulationaha.121.056589 · Cited by 255
Bacteria Boost Mammalian Host NAD Metabolism by Engaging the Deamidated Biosynthesis Pathway
Shats, I., Williams, J. G., Liu, J., Makarov, M. V., Wu, X., Lih, F. B., Deterding, L. J., Lim, C., Xu, X., Randall, T. A., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.02.001 · Cited by 242
Self-citationImplications of altered NAD metabolism in metabolic disorders
Okabe, K., Yaku, K., Tobe, K., & Nakagawa, T. (2019) · Journal of Biomedical Science · doi:10.1186/s12929-019-0527-8 · Cited by 223
“Interestingly, NRK1 also regulates NAD synthesis from NMN [51].”
BackgroundInfluentialNicotinamide Riboside—The Current State of Research and Therapeutic Uses
Mehmel, M., Jovanović, N., & Spitz, U. (2020) · Nutrients · doi:10.3390/nu12061616 · Cited by 221
“While NAD+ and NMN are being converted to NR extracellularly by CD73 [28], their cellular conversion depends on the NMRK pathway [153,160].”
BackgroundInfluentialModulating NAD + metabolism, from bench to bedside
Katsyuba, E., & Auwerx, J. (2017) · The EMBO Journal · doi:10.15252/embj.201797135 · Cited by 221
“Interestingly, it has been recently reported that NRK1 is required for NAD + synthesis not only from the exogenously administered NR, but also NMN (Ratajczak et al , 2016).”
Self-citationRole of NAD+ and mitochondrial sirtuins in cardiac and renal diseases
Hershberger, K. A., Martin, A. S., & Hirschey, M. D. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.5 · Cited by 218
Conze, D., Brenner, C., & Kruger, C. L. (2019) · Scientific Reports · doi:10.1038/s41598-019-46120-z · Cited by 210
Self-citationNAMPT and NAPRT: Two Metabolic Enzymes With Key Roles in Inflammation
Audrito, V., Messana, V. G., & Deaglio, S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00358 · Cited by 208
“On the other side, NMN can be also used by CD73, which generates nicotinamide riboside (NR) (66, 70), that, likely through equilibrative nucleoside transporters (ENTs), can be imported as NADprecursor (71, 72) (Figure 1).”
BackgroundZhao, Z. Y., Xie, X. J., Li, W. H., Liu, J., Chen, Z., Zhang, B., Li, T., Li, S. L., Lu, J. G., Zhang, L., et al. (2019) · iScience · doi:10.1016/j.isci.2019.05.001 · Cited by 178
“, 2012), which can then be taken up by nucleoside transporters (Nikiforov et al., 2011; Ratajczak et al., 2016).”
BackgroundHong, W., Mo, F., Zhang, Z., Huang, M., & Wei, X. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00246 · Cited by 174
McReynolds, M. R., Chellappa, K., & Baur, J. A. (2020) · Experimental Gerontology · doi:10.1016/j.exger.2020.110888 · Cited by 163
Ye, M., Zhao, Y., Wang, Y., Xie, R., Tong, Y., Sauer, J.-D., & Gong, S. (2022) · Nature Nanotechnology · doi:10.1038/s41565-022-01137-w · Cited by 163
Li, H.-R., Liu, Q., Zhu, C.-L., Sun, X.-Y., Sun, C.-Y., Yu, C.-M., Li, P., Deng, X.-M., & Wang, J.-F. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102745 · Cited by 163
Administration of nicotinamide riboside prevents oxidative stress and organ injury in sepsis
Hong, G., Dong, Z., Zhang, L., Ni, R., Wang, G., Fan, G., Lu, Z., & Peng, T. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.05.073 · Cited by 150
“NR is converted into NAD sequentially by NR kinase 1/2 and nicotinamide mononucleotide adenylyltransferase [14,15].”
InfluentialDollerup, O. L., Chubanava, S., Agerholm, M., Søndergård, S. D., Altıntaş, A., Møller, A. B., Høyer, K. F., Ringgaard, S., Stødkilde‐Jørgensen, H., Lavery, G. G., et al. (2020) · The Journal of Physiology · doi:10.1113/jp278752 · Cited by 145
“The Journal of Physiology C© 2019 The Physiological Society NAD+ levels in skeletal muscle (Ratajczak et al. 2016; Fletcher et al. 2017).”
BackgroundNicotinamide adenine dinucleotide is transported into mammalian mitochondria
Davila, A., Liu, L., Chellappa, K., Redpath, P., Nakamaru-Ogiso, E., Paolella, L. M., Zhang, Z., Migaud, M. E., Rabinowitz, J. D., & Baur, J. A. (2018) · eLife · doi:10.7554/elife.33246 · Cited by 142
Self-citationThe role of NAD+ metabolism and its modulation of mitochondria in aging and disease
Yusri, K., Jose, S., Vermeulen, K. S., Tan, T. C. M., & Sorrentino, V. (2025) · npj Metabolic Health and Disease · doi:10.1038/s44324-025-00067-0 · Cited by 215
“However, exposure of compounds like NR and NMN to serum results in their low stability and degradation in the blood 68,124 .”
InfluentialNicotinamide Mononucleotide: Exploration of Diverse Therapeutic Applications of a Potential Molecule
Poddar, S. K., Sifat, A. E., Haque, S., Nahid, N. A., Chowdhury, S., & Mehedi, I. (2019) · Biomolecules · doi:10.3390/biom9010034 · Cited by 136
“Following this, the ubiquitously expressed NRK1 helps the subsequent conversion of NR to NMN [26].”
BackgroundCambronne, X. A., & Kraus, W. L. (2020) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2020.05.010 · Cited by 137
Preclinical and clinical evidence of NAD+ precursors in health, disease, and ageing
Reiten, O. K., Wilvang, M. A., Mitchell, S. J., Hu, Z., & Fang, E. F. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111567 · Cited by 144
“For example, some studies showed that extracellular NMN is dephosphorylated to NR for cellular uptake (Ratajczak et al., 2016), while another report argued SLC12A8 was a cellular transporter of NMN whereby the data got challenges (Grozio et al.”
NAD metabolism: Role in senescence regulation and aging
Chini, C. C. S., Cordeiro, H. S., Tran, N. L. K., & Chini, E. N. (2023) · Aging Cell · doi:10.1111/acel.13920 · Cited by 165
“While some studies suggest that NMN is converted to NR before its cellular uptake (Kulikova et al., 2019; Ratajczak et al., 2016), others propose that it gets into the cell through a specific NMN transporter, Slc12a8, at least in the intestine (Grozio et al., 2019).”
BackgroundMartin, A. S., Abraham, D. M., Hershberger, K. A., Bhatt, D. P., Mao, L., Cui, H., Liu, J., Liu, X., Muehlbauer, M. J., Grimsrud, P. A., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.93885 · Cited by 128
“Increased Nmrk2 suggests an enhanced capacity of the FXN-KO heart to take up exogenous NAD+ precursors NR and NMN (27), and decreased Nampt suggests reduced de novo synthesis of NAD+ in the FXN-KO heart.”
BackgroundGiroud‐Gerbetant, J., Joffraud, M., Giner, M. P., Cercillieux, A., Bártová, S., Makarov, M. V., Perez, R. Z., Sánchez-García, J. L., Houtkooper, R. H., Migaud, M. E., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.013 · Cited by 134
“Protein and mRNA analysis Total mRNAs were extracted, processed, and quantified as described previously [20].”
BackgroundMethodInfluentialSelf-citationRegulation of and challenges in targeting NAD+ metabolism
Migaud, M. E., Ziegler, M., & Baur, J. A. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-024-00752-w · Cited by 159
Self-citationFletcher, R. S., Ratajczak, J., Doig, C. L., Oakey, L. A., Callingham, R., Xavier, G. D. S., Garten, A., Elhassan, Y., Redpath, P., Migaud, M. E., et al. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.05.011 · Cited by 134
“They identified a requirement for NMN to be metabolized extracellularly to NR before hepatic uptake, then re-phosphorylated by NRK1 back to NMN [28].”
BackgroundInfluentialSelf-citationThe Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update
Song, Q., Zhou, X., Xu, K., Liu, S., Zhu, X., & Yang, J. J. (2023) · Advances in Nutrition · doi:10.1016/j.advnut.2023.08.008 · Cited by 128
“After NR enters the cell through equilibrative nucleoside transporters (ENT1, ENT2, and ENT4), it is phosphorylated by NRK1 and NRK2 to generate NMN [162,163,166,167].”
BackgroundKlimova, N., Fearnow, A. D., Long, A., & Kristián, T. (2019) · Experimental Neurology · doi:10.1016/j.expneurol.2019.113144 · Cited by 111
“NMN is metabolized extracellularly to nicotinamide ribose (NR) that is transported into the cell and converted to NAD+ (Ratajczak et al., 2016).”
BackgroundThe chemistry of the vitamin B3 metabolome
Makarov, M. V., Trammell, S. A. J., & Migaud, M. E. (2018) · Biochemical Society Transactions · doi:10.1042/bst20180420 · Cited by 116
Self-citationRegulation and Function of Extracellular Nicotinamide Phosphoribosyltransferase/Visfatin
Carbone, F., Liberale, L., Bonaventura, A., Vecchié, A., Casula, M., Cea, M., Monacelli, F., Caffa, I., Bruzzone, S., Montecucco, F., et al. (2017) · Comprehensive physiology · doi:10.1002/cphy.c160029 · Cited by 125
“Similarly, the detection of NMN plasma concentrations remains controversial (77, 155, 159).”
Antiaging agents: safe interventions to slow aging and healthy life span extension
Liu, J. (2022) · Natural Products and Bioprospecting · doi:10.1007/s13659-022-00339-y · Cited by 118
“Another study showed that NMN (32) is metabolized extracellularly to produce NR, which is then converted into NAD+ intracellular [138].”
BackgroundJokinen, R., Pirnes-Karhu, S., Pietiläinen, K. H., & Pirinen, E. (2017) · Redox Biology · doi:10.1016/j.redox.2017.02.011 · Cited by 109
Glaucoma as a Metabolic Optic Neuropathy: Making the Case for Nicotinamide Treatment in Glaucoma
Williams, P. A., Harder, J. M., & John, S. W. M. (2017) · Journal of Glaucoma · doi:10.1097/ijg.0000000000000767 · Cited by 102
Regulation of NAD+ metabolism in aging and disease
Chu, X., & Raju, R. P. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154923 · Cited by 115
de Guia, R. M., Agerholm, M., Nielsen, T. S., Consitt, L. A., Søgaard, D., Helge, J. W., Larsen, S., Brandauer, J., Houmard, J. A., & Treebak, J. T. (2019) · Physiological Reports · doi:10.14814/phy2.14139 · Cited by 99
“1) (Bieganowski and Brenner 2004; Ratajczak et al. 2016).”
Kynurenine pathway metabolism and neuroinflammatory disease
Braidy, N., & Grant, R. (2017) · Neural Regeneration Research · doi:10.4103/1673-5374.198971 · Cited by 97
“…nicotinamide phosphoribosyl transferase (NAMPT) converts NM to nicotinamide mononucleotide (NMN) and then to NAD + by the action of NMNAT1, 2, and 3 in the presence of ATP, or (3) phosphorylation of nicotinamide riboside (NR) to NMN by NR kinases (NRKs) (Ratajczak et al., 2016) ( Figure 1A and B ).”
Nicotinamide mononucleotide alters mitochondrial dynamics by SIRT3‐dependent mechanism in male mice
Klimova, N., Long, A., & Kristián, T. (2019) · Journal of Neuroscience Research · doi:10.1002/jnr.24397 · Cited by 99
“However, plasma NR levels were not affected by NMN administration (Ratajczak et al., 2016).”
BackgroundMethodInfluentialLiao, B., Zhao, Y., Wang, D., Zhang, X., Xuan-ming, H., & Hu, M. (2021) · Journal of the International Society of Sports Nutrition · doi:10.1186/s12970-021-00442-4 · Cited by 108
“For example, in contrast to NMN, NR was observed to be unstable in rodent plasma [13].”
BackgroundTargeting NAD+ in Metabolic Disease: New Insights Into an Old Molecule
Elhassan, Y., Philp, A., & Lavery, G. G. (2017) · Journal of the Endocrine Society · doi:10.1210/js.2017-00092 · Cited by 101
“Illustrating this, administered NR is converted to Nam in the circulation before entering the cell [208, 227], whereas NMN is transformed extracellularly into NR, which then enters the cell and converts into NAD+ [227].”
BackgroundCircadian and Feeding Rhythms Orchestrate the Diurnal Liver Acetylome
Mauvoisin, D., Atger, F., Dayon, L., Galindo, A. N., Wang, J., Martín, E., Silva, L. D., Montoliu, I., Collino, S., Martin, F., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.07.065 · Cited by 98
“Indeed, the circadian clock controls NAMPT, involved in the synthesis of NAD + through the salvage pathway or from the food-contained nicotinamide (NAM), but also NRK1, involved in the synthesis of NAD + from NR and NMN (Ratajczak et al., 2016; Figure 7A).”
InfluentialSelf-citationRole of endothelial NAD+deficiency in age-related vascular dysfunction
Csiszár, A., Tarantini, S., Yabluchanskiy, A., Balasubramanian, P., Kiss, T., Farkas, E., Baur, J. A., & Ungvari, Z. I. (2019) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00039.2019 · Cited by 101
Yan, J., Zhang, J., Wang, Y., et al. (2023) · Advanced Science · doi:10.1002/advs.202207448 · Cited by 90
Reduced nicotinamide adenine dinucleotide phosphate in redox balance and diseases: a friend or foe?
Koju, N., Qin, Z., & Sheng, R. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00838-7 · Cited by 100
“Similarly, in mice, the administration of NR augmented NAD levels in muscle, liver, brain, and brown adipose tissue, and such effect was abolished in NRK1 knockout mice [32, 53].”
BackgroundExtracellular NAD+ enhances PARP-dependent DNA repair capacity independently of CD73 activity
Wilk, A. M., Hayat, F., Cunningham, R., Li, J., Garavaglia, S., Zamani, L., Ferraris, D. M., Sýkora, P., Andrews, J., Clark, J., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-57506-9 · Cited by 98
Self-citationDollerup, O. L., Trammell, S. A. J., Hartmann, B., Holst, J. J., Christensen, B., Møller, N., Gillum, M. P., Treebak, J. T., & Jessen, N. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-01081 · Cited by 77
Self-citationVaur, P., Brugg, B., Mericskay, M., Li, Z., Schmidt, M. S., Vivien, D., Orset, C., Jacotot, E. D., Brenner, C., & Duplus, E. (2017) · The FASEB Journal · doi:10.1096/fj.201700221rr · Cited by 90
Self-citationMateuszuk, Ł., Campagna, R., Kutryb-Zając, B., Kuś, K., Słominska, E. M., Smolenski, R. T., & Chlopicki, S. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114019 · Cited by 81
“NR is phosphorylated by nicotinamide riboside kinases (NRK1, NRK2) to endogenous NMN [53,17].”
BackgroundHamity, M. V., White, S. R., Walder, R. Y., Schmidt, M. S., Brenner, C., & Hammond, D. L. (2017) · Pain · doi:10.1097/j.pain.0000000000000862 · Cited by 79
“Candidate mechanisms include mitochondrial dysfunction, peripheral nerve degeneration, nitro-oxidative stress, modulation of ion channels, and glial activation.12,17,24,28,29 In recent years, evidence has accrued that nicotinamide adenine dinucleotide (NAD1), an essential redox coenzyme,48,70 plays an important role i…”
InfluentialSelf-citationSubcellular compartmentalization of NAD+ and its role in cancer: A sereNADe of metabolic melodies
Zhu, Y., Liu, J., Park, J., Rai, P., & Zhai, R. G. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.04.002 · Cited by 86
“Alternatively, extracellular NAD+ can be degraded to NMN, which is further metabolized by NR kinases (NRKs) to NR that can be imported as NAD+ precursors, likely through equilibrative nucleoside transporters (ENTs) (Nikiforov et al., 2011; Ratajczak et al., 2016).”
BackgroundTannous, C., Booz, G. W., Altara, R., Muhieddine, D. H., Mericskay, M., Refaat, M. M., & Zouein, F. A. (2020) · Acta Physiologica · doi:10.1111/apha.13551 · Cited by 84
BST1 regulates nicotinamide riboside metabolism via its glycohydrolase and base-exchange activities
Yaku, K., Palikhe, S., Izumi, H., Yoshida, T., Hikosaka, K., Hayat, F., Karim, M., Iqbal, T., Nitta, Y., Sato, A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27080-3 · Cited by 76
Self-citationEar, P. H., Chadda, A., Gumusoglu, S. B., Schmidt, M. S., Vogeler, S., Malicoat, J., Kadel, J., Moore, M. M., Migaud, M. E., Stevens, H. E., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.01.007 · Cited by 72
“NMNAT1 forward: TGGCTCTTTTAACCCCATCAC (Ratajczak et al., 2016)”
MethodInfluentialSelf-citationNicotinamide Adenine Dinucleotide Metabolism and Neurodegeneration
Pehar, M., Harlan, B. A., Killoy, K. M., & Vargas, M. R. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7145 · Cited by 78
“As mentioned earlier, NR is a naturally occurring NAD + precursor that can be imported into the cell, where it is phosphorylated by NRKs to produce NMN (117, 135).”
Pham, T. X., Bae, M., Kim, M., Lee, Y., Hu, S., Kang, H., Park, Y., & Lee, J. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.06.009 · Cited by 76
“The enzyme CD73 converts NMN to NR [40].”
BackgroundDiverse therapeutic efficacies and more diverse mechanisms of nicotinamide
Song, S. B., Park, J., Chung, G. J., Lee, I. H., & Hwang, E. S. (2019) · Metabolomics · doi:10.1007/s11306-019-1604-4 · Cited by 73
Reduced nicotinamide mononucleotide is a new and potent NAD + precursor in mammalian cells and mice
Perez, R. Z., Tammaro, A., Schomakers, B. V., Scantlebery, A. M. L., Denis, S. W., Elfrink, H. L., Giroud‐Gerbetant, J., Cantó, C., López‐Leonardo, C., McIntyre, R. L., et al. (2021) · The FASEB Journal · doi:10.1096/fj.202001826r · Cited by 83
Self-citationHu, Q., Wu, D., Walker, M. A., Wang, P., Tian, R., & Wang, W. (2021) · Cell Reports Methods · doi:10.1016/j.crmeth.2021.100116 · Cited by 75
“Alternatively, NMN could be first converted into NR by CD73 in the extracellular environment (Ratajczak et al., 2016).”
Dietary strategies with anti-aging potential: Dietary patterns and supplements
Duan, H., Pan, J., Guo, M., Li, J., Yu, L., & Fan, L. (2022) · Food Research International · doi:10.1016/j.foodres.2022.111501 · Cited by 77
Kynurenines in the Pathogenesis of Multiple Sclerosis: Therapeutic Perspectives
Biernacki, T., Sandi, D., Bencsik, K., & Vécsei, L. (2020) · Cells · doi:10.3390/cells9061564 · Cited by 70
Cellular Compartmentation and the Redox/Nonredox Functions of NAD +
Kulkarni, C. A., & Brookes, P. S. (2019) · Antioxidants and Redox Signaling · doi:10.1089/ars.2018.7722 · Cited by 72
“However, recent studies showed that even in hepatocytes, NRK1 is necessary and rate limiting for the use of exogenous NMN for NAD synthesis (135).”
BackgroundInfluentialSayers, S. R., Beavil, R. L., Fine, N. H. F., Huang, G. C., Choudhary, P., Pacholarz, K. J., Barran, P. E., Butterworth, S., Mills, C. E., Cruickshank, J. K., et al. (2019) · Diabetologia · doi:10.1007/s00125-019-05029-y · Cited by 63
Absence of evidence that Slc12a8 encodes a nicotinamide mononucleotide transporter
Schmidt, M. S., & Brenner, C. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0085-0 · Cited by 64
Self-citationHong, Y., Liu, M., Wang, L., Zu, Y., Wu, C., Li, C., Zhang, R., Lu, H., Li, F., Xi, S., et al. (2022) · Cell Research · doi:10.1038/s41422-022-00651-9 · Cited by 72
Kimball, A. B., Alora-Palli, M. B., Tamura, M., Mullins, L. A., Soh, C., Binder, R. L., Houston, N. A., Conley, E. D., Tung, J. Y., Annunziata, N. E., et al. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.09.012 · Cited by 62
Emerging potential benefits of modulating NAD + metabolism in cardiovascular disease
Matasic, D. S., Brenner, C., & London, B. (2017) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00409.2017 · Cited by 65
“Upon entry in the cell, NR is then phosphorylated to NMN by NMRK isozymes NMRK1 and NMRK2 within the cytoplasm (28, 84).”
Self-citationSubcellular NAD+ pools are interconnected and buffered by mitochondrial NAD+
Høyland, L. E., VanLinden, M. R., Niere, M., Strømland, Ø., Sharma, S. A., Dietze, J., Tolås, I., Lucena, E., Bifulco, E., Sverkeli, L. J., et al. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01174-w · Cited by 77
Self-citationNAD+ metabolism as a target for metabolic health: have we found the silver bullet?
Connell, N. J., Houtkooper, R. H., & Schrauwen, P. (2019) · Diabetologia · doi:10.1007/s00125-019-4831-3 · Cited by 63
Vignier, N., Chatzifrangkeskou, M., Rodríguez, B. M., Mericskay, M., Mougenot, N., Wahbi, K., Bonne, G., & Muchir, A. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy278 · Cited by 60
NAD+ and NAFLD – caution, causality and careful optimism
Dall, M., Hassing, A. S., & Treebak, J. T. (2021) · The Journal of Physiology · doi:10.1113/jp280908 · Cited by 57
“One study found that extracellular NMN must be converted to NR for uptake and processing into NAD+ (Ratajczak et al. 2016).”
BackgroundNAD+ Deficits in Age-Related Diseases and Cancer
Garrido, A., & Djouder, N. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.06.001 · Cited by 56
Lloret, A., & Beal, M. F. (2019) · Neurochemical Research · doi:10.1007/s11064-019-02809-1 · Cited by 52
Endogenous nicotinamide riboside metabolism protects against diet-induced liver damage
Sambeat, A., Ratajczak, J., Joffraud, M., Sanchez-Garcia, J. L., Giner, M. P., Valsesia, A., Giroud‐Gerbetant, J., Valera‐Alberni, M., Cercillieux, A., Boutant, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12262-x · Cited by 52
Self-citationNAD+: A key metabolic regulator with great therapeutic potential
Sultani, G., Samsudeen, A., Osborne, B., & Turner, N. A. (2017) · Journal of Neuroendocrinology · doi:10.1111/jne.12508 · Cited by 61
Enzymology of extracellular NAD metabolism
Gasparrini, M., Sorci, L., & Raffaelli, N. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03742-1 · Cited by 56
Ye, C., Qi, L., Li, X., Wang, J., Yu, J., Zhou, B., Guo, C., Chen, J., & Zheng, S. S. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-0513-5 · Cited by 54
Pharmacology and Potential Implications of Nicotinamide Adenine Dinucleotide Precursors
She, J., Sheng, R., & Qin, Z. (2021) · Aging and Disease · doi:10.14336/ad.2021.0523 · Cited by 53
“Moreover, the concentration of NAAD, a metabolite that is supposed to increase after the administration of NA instead of NR [94], was also assessed, which was found to be significantly increased, although a slight delay in the increase in the concentration of NAAD was observed relative to other metabolites, NAAD may b…”
BackgroundResultEmerging strategies, applications and challenges of targeting NAD+ in the clinic
Zhang, J., Wang, H., Lautrup, S., Nilsen, H. L., Treebak, J. T., Watne, L. O., Selbæk, G., Wu, L. E., Omland, T., Pirinen, E., et al. (2025) · Nature Aging · doi:10.1038/s43587-025-00947-6 · Cited by 66
“278), while NMN typically requires dephosphorylation to NR before cellular uptake 208 , although some evidence suggests direct transport via SLC12C8 (ref.”
Self-citationRoles of NAD + in Health and AgingPreprint
Lautrup, S., Hou, Y., Fang, E. F., & Bohr, V. A. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041193 · Cited by 56
Dall, M., Penke, M., Sulek, K., Matz‐Soja, M., Holst, B., Garten, A., Kieß, W., & Treebak, J. T. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2018.01.025 · Cited by 46
Integrated Stress Response Potentiates Ponatinib-Induced Cardiotoxicity
Yan, G., Han, Z., Kwon, Y., Jousma, J., Nukala, S. B., Prosser, B. L., Du, X., Pinho, S., Ong, S., Lee, W. H., et al. (2024) · Circulation Research · doi:10.1161/circresaha.123.323683 · Cited by 43
“62–64 Encouragingly, we found that restoring ATP levels with NMN significantly rescued the deterioration of cell viability in ponatinib-treated hiPSC-CMs (Figure 5A).”
BackgroundAgerholm, M., Dall, M., Jensen, B. A. H., Prats, C., Madsen, S., Basse, A. L., Graae, A.-S., Risis, S., Goldenbaum, J., Quistorff, B., et al. (2017) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00213.2017 · Cited by 42
Metadata
- Authors
- Ratajczak, J., Joffraud, M., Trammell, S. A. J., Ras, R., Canela, N., Boutant, M., Kulkarni, S. S., Rodrigues, M., Redpath, P., Migaud, M. E., Auwerx, J., Yanes, O., Brenner, C., & Cantó, C.
- Affiliations
- École Polytechnique Fédérale de Lausanne (CH)
- University of Iowa (US)
- Centre for Omic Sciences (ES)
- Queen's University Belfast (GB)
- Corresponding author
- Brenner, Charles
- Cantó, Carles
- ORCID
- Venue
- Nature Communications
- Published
- 2016-10-11
- Volume
- 7
- Issue
- 1
- Pages
- 13103-13103
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC5476803
- OpenAlex
- W2531686927
- Cited by
- 378
- References
- 46
- Citations by year
- 2026: 34 · 2025: 35 · 2024: 48 · 2023: 46 · 2022: 38 · 2021: 40 · 2020: 31 · 2019: 43 · 2018: 28 · 2017: 31 · 2016: 2
- FWCI
- 19.91
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- Research Portal (Queen's University Belfast) (publishedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
- Funders
- Roy J. Carver Charitable Trust
- École Polytechnique Fédérale de Lausanne
- National Institutes of Health
- Directorate for Biological Sciences
- Biotechnology and Biological Sciences Research Council (BB/N001842/1)
- National Institute on Alcohol Abuse and Alcoholism (R21AA022371)
- National Heart, Lung, and Blood Institute (R01HL108379)
- National Institute of General Medical Sciences (T32GM008629)
- Topics
- Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
- Health Sciences › Nursing › Nutrition and Dietetics › Folate and B Vitamins Research
- Keywords
- nicotinamide mononucleotide, nicotinamide riboside, NAD+ synthesis, NAD+ precursors, sirtuins, poly(ADP-ribose) polymerase, NAD+ supplementation
- MeSH terms
- Animals, Humans, Injections, Intraperitoneal, Mammals, NAD, Niacinamide, Nicotinamide Mononucleotide, Pyridinium Compounds, Phosphotransferases (Alcohol Group Acceptor), Mice, Knockout, Hepatocytes, Hep G2 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.